Suppr超能文献

他汀类药物对 HDL-C 的影响:与 LDL-C 变化无关的复杂过程:VOYAGER 数据库分析。

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.

机构信息

Heart Research Institute, Sydney, Australia.

出版信息

J Lipid Res. 2010 Jun;51(6):1546-53. doi: 10.1194/jlr.P002816. Epub 2009 Dec 2.

Abstract

The relationship between statin-induced increases in HDL cholesterol (HDL-C) concentration and statin-induced decreases in LDL cholesterol (LDL-C) is unknown. The effects of different statins on HDL-C levels, relationships between changes in HDL-C and changes in LDL-C, and predictors of statin-induced increases in HDL-C have been investigated in an individual patient meta-analysis of 32,258 dyslipidemic patients included in 37 randomized studies using rosuvastatin, atorvastatin, and simvastatin. The HDL-C raising ability of rosuvastatin, and simvastatin was comparable, with both being superior to atorvastatin. Increases in HDL-C were positively related to statin dose with rosuvastatin and simvastatin but inversely related to dose with atorvastatin. There was no apparent relationship between reduction in LDL-C and increase in HDL-C, whether analyzed overall for all statins (correlation coefficient = 0.005) or for each statin individually. Percentage increase in apolipoprotein A-I was virtually identical to that of HDL-C at all doses of the three statins. Baseline concentrations of HDL-C and triglyceride (TG) and presence of diabetes were strong, independent predictors of statin-induced elevations of HDL-C. Statins vary in their HDL-C raising ability. The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C.

摘要

他汀类药物引起的高密度脂蛋白胆固醇(HDL-C)浓度升高与他汀类药物引起的低密度脂蛋白胆固醇(LDL-C)降低之间的关系尚不清楚。本个体患者荟萃分析纳入了 37 项随机研究中的 32258 例血脂异常患者,旨在评估不同他汀类药物对 HDL-C 水平的影响、HDL-C 变化与 LDL-C 变化之间的关系,以及他汀类药物引起 HDL-C 升高的预测因素。结果显示,瑞舒伐他汀和辛伐他汀升高 HDL-C 的能力与阿托伐他汀相当,且均优于阿托伐他汀。瑞舒伐他汀和辛伐他汀的 HDL-C 升高与他汀类药物剂量呈正相关,但阿托伐他汀的 HDL-C 升高与剂量呈负相关。总体上分析所有他汀类药物(相关系数=0.005)或单独分析每种他汀类药物,HDL-C 降低与 HDL-C 升高之间均无明显关系。三种他汀类药物在所有剂量下,载脂蛋白 A-I 的百分比增加与 HDL-C 几乎相同。HDL-C 和三酰甘油(TG)的基线浓度以及糖尿病的存在是他汀类药物引起 HDL-C 升高的强有力独立预测因素。他汀类药物在升高 HDL-C 的能力方面存在差异。三种他汀类药物均可独立于 LDL-C 降低来升高 HDL-C。然而,基线 HDL-C 和三酰甘油以及糖尿病的存在是他汀类药物引起 HDL-C 升高的预测因素。

相似文献

1
Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.
J Lipid Res. 2010 Jun;51(6):1546-53. doi: 10.1194/jlr.P002816. Epub 2009 Dec 2.
2
Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
Nutr Metab Cardiovasc Dis. 2012 Sep;22(9):697-703. doi: 10.1016/j.numecd.2012.03.003. Epub 2012 Jun 16.
4
Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database.
Atherosclerosis. 2017 Oct;265:54-59. doi: 10.1016/j.atherosclerosis.2017.08.014. Epub 2017 Aug 19.
6
Pitavastatin: novel effects on lipid parameters.
Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X.

引用本文的文献

1
HDL metabolism and function in diabetes mellitus.
Nat Rev Endocrinol. 2025 Sep 17. doi: 10.1038/s41574-025-01176-y.
2
Low HDL-The Challenge.
Clin Med Res. 2025 Aug;23(2):60-66. doi: 10.3121/cmr.2025.1970.
3
Optimizing statin therapy in HIV-infected patients: a review of pharmacotherapy considerations.
BMC Cardiovasc Disord. 2025 May 31;25(1):421. doi: 10.1186/s12872-025-04887-2.
5
Dynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program.
Rev Cardiovasc Med. 2025 Jan 13;26(1):25399. doi: 10.31083/RCM25399. eCollection 2025 Jan.
8
Explaining adverse cholesterol levels and distinct gender patterns in an Indonesian population compared with the U.S.
Econ Hum Biol. 2024 Aug;54:101403. doi: 10.1016/j.ehb.2024.101403. Epub 2024 May 25.
9
Statin therapy improves outcomes in infective endocarditis: evidence from a meta-analysis.
Egypt Heart J. 2024 Jun 7;76(1):70. doi: 10.1186/s43044-024-00495-1.
10
Targeting NPC1 in Renal Cell Carcinoma.
Cancers (Basel). 2024 Jan 25;16(3):517. doi: 10.3390/cancers16030517.

本文引用的文献

2
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
3
Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit.
Cardiovasc Drugs Ther. 2008 Aug;22(4):321-38. doi: 10.1007/s10557-008-6113-z. Epub 2008 Jun 14.
6
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
Am J Cardiol. 2007 Mar 1;99(5):681-5. doi: 10.1016/j.amjcard.2006.09.117. Epub 2007 Jan 4.
7
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
JAMA. 2007 Feb 7;297(5):499-508. doi: 10.1001/jama.297.5.499.
8
Coronary atherosclerosis can regress with very intensive statin therapy.
Cleve Clin J Med. 2006 Oct;73(10):937-44. doi: 10.3949/ccjm.73.10.937.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验